MannKind Corp
NASDAQ:MNKD

Watchlist Manager
MannKind Corp Logo
MannKind Corp
NASDAQ:MNKD
Watchlist
Price: 3.86 USD 1.05%
Market Cap: 1.2B USD

Operating Margin
MannKind Corp

27.3%
Current
-28%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.3%
=
Operating Profit
81.1m
/
Revenue
297.6m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
MannKind Corp
NASDAQ:MNKD
1.2B USD
27%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
329.9B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
163B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
137.6B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.5B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
127.8B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.2B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

MannKind Corp
Glance View

Market Cap
1.2B USD
Industry
Biotechnology

MannKind Corp. stands as a fascinating player in the biotech landscape, primarily due to its focus on innovative drug delivery systems that aim to redefine patient experience and therapeutic efficacy. Founded with the intention of creating transformative medicinal solutions, the company is best known for its flagship product, Afrezza, an inhalable form of insulin designed to manage diabetes. This unique delivery method not only enhances the speed at which insulin begins to act within the body, but also offers a discreet and user-friendly alternative to traditional injectable options. Driven by a blend of science and practicality, MannKind's efforts are centered around enhancing quality of life for patients, marking its territory in a niche, yet crucial, segment of the pharmaceutical market. MannKind generates revenue by producing and distributing its highly specialized products, leveraging partnerships with larger pharmaceutical companies to expand its market reach. By optimizing their drug delivery systems, they aim to position themselves competitively, offering solutions that stand out in a crowded industry. Beyond Afrezza, MannKind seeks to harness its proprietary Technosphere technology platform, exploring applications beyond diabetes to potentially treat other conditions. This approach not only broadens their market horizon but also diversifies potential revenue streams, allowing MannKind to maintain a steady course in the volatile currents of the biotech sector. In essence, MannKind's business strategy is a calculated blend of ingenuity and collaboration, with a clear emphasis on meeting unmet medical needs effectively.

MNKD Intrinsic Value
4.66 USD
Undervaluation 17%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
27.3%
=
Operating Profit
81.1m
/
Revenue
297.6m
What is the Operating Margin of MannKind Corp?

Based on MannKind Corp's most recent financial statements, the company has Operating Margin of 27.3%.

Back to Top